PROJECT SUMMARY
Antibodies are critical mediators of immune protection against pathogens, simultaneously acting to neutralize
entry and activate innate immune cells through interaction between the antibody Fc domain and Fc-receptors
(FcRs) on innate immune cells. Leveraging Fc-mediated activation in monoclonal antibody-based therapies is
increasingly being investigated for the treatment of infectious diseases but the precise mechanisms and breadth
of functions that can be induced by range of FcR-bearing immune cells is still unclear. However, these efforts
are limited by the fact that we do not fully understand the spectrum of effector functions and effector programs
that are induced via different FcRs, which could greatly impact efficacy and safety of mAb-based therapeutics.
Moreover, as some innate immune cells such as monocytes express multiple FcRs, understanding how these
pathways interact will help in the development of rational antibody design strategies to effectively harness innate
immune cells against a variety of pathogens.
There are four activating FcRs that bind IgG and are expressed on innate immune cells (Fc¿R1, Fc¿R2A,
Fc¿R3A, and Fc¿R3B) and one inhibitory receptor (Fc¿R2B). The interplay between these receptors can impact
Fc-effector functions, especially in monocytes that express multiple FcRs. Moreover, antibody-mediated
activation of non-classical monocytes that express 3 activating Fc¿Rs must balance protection and pathology,
as antibody-dependent enhancement of infection/disease has been observed in some contexts. Thus, defining
the transcriptional profiles of FcR-mediated activation of will be critical to better predict in vivo activity of
immunotherapies and antibodies induced by vaccination or infection. To that end, we propose to begin to
generate an ‘FcR Effector Atlas’ that defines the anti-pathogen pathways that are induced in distinct innate
immune cell types mediated by different FcRs. The Atlas can be used to map the pathways induced across all
innate immune cells to help guide development of optimally efficacious and safe antibody therapeutics against
infectious diseases.
By combining Fc-engineered antibodies that facilitate individual or combinatorial activation of specific FcRs
and nascent transcriptomics, the goal of this proposal is pioneer an approach to generate the Atlas in
nonclassical monocytes. We will use SARS-CoV-2-specfic Fc-engineered monoclonal antibodies as a model
system to specifically engage different FcRs on monocytes to define the FcR-mediated transcriptional network
using capped small RNA-sequencing (csRNA-seq) that enables transcriptional profiling of nascent RNA
transcriptional start sites. Further, we will functionally link induction of specific pathways to restriction of SARS-
CoV-2 infection. Together, the approaches and results generated from this proposal will contribute to our
fundamental understanding of how antibodies leverage innate immunity and can be used to guide development
of highly effective and safe immunotherapeutics for infectious diseases and beyond.
